Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer

American Journal of Managed Care

Volumn 17, Issue 7, 2011, Pages 455-464

  Vanderlaan, Burton F ^a   Broder, Michael S ^b   Chang, Eunice Y ^b   Oratz, Ruth ^c   Bentley, Tanya G K ^b  

^a AETNA   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HEALTH CARE COST; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MEDICARE; MYALGIA; NAUSEA AND VOMITING; NEUROMOTOR TOXICITY; NEUROSENSORY TOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; PHLEBITIS; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; WEIGHT GAIN; WEIGHT REDUCTION;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 79960802694     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479-484. (Pubitemid 19062522)
2. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-1682. (Pubitemid 27508191)
3. Fisher B, Jeong JH, Bryant J, et al; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymphnode- negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364(9437):858-868.
4. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734. (Pubitemid 46622311)
5. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826. (Pubitemid 40051905)
6. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25.
7. Dowsett M, Cuzick J, Wales C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010:28(11):1829-1834.
8. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. V.1.2010. http://www.nccn.org/professionals/physician- gls/PDF/breast.pdf. Accessed September 29, 2010.
9. Harris L, Fritsche H, Mennel R, et al American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312. (Pubitemid 350232263)
10. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28(10):1671-1676.
11. Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG. A retrospective analysis of the impact of Oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX.
12. Mumby PB, Lo SS, Norton J, et al. Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX.
13. Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX.
14. Ben-Baruch N, Hammerman A, Klang S, Liebemann A. A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early-stage breast cancer patients. J Clin Oncol. 2007;25(18S; June 20 suppl).
15. Albain KS, Barlow WE, Shak S, et al Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol. 2010;11(1):55-65.
16. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109(6):1011-1018. (Pubitemid 46435378)
17. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer [published correction appears in Am J Manag Care. 2005;11(8):476]. Am J Manag Care. 2005;11(5):313-324. (Pubitemid 40646936)
18. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health. 2010;13(4):381-387.
19. SEER: Surveillance Epidemiology and End Results Program of the National Cancer Institute. SEER*Stat Software. Version 6.4.4. http://seer.cancer. gov/seerstat. Published April 24, 2008. Accessed November 8, 2010.
20. Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol. 2005;23(4):783-791. (Pubitemid 46224177)
21. Oratz R, Kim B, Chao C, et al. Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive and estrogen receptor-positive breast cancer. J Oncol Pract. In press.
22. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2007;3(4):182-186. (Pubitemid 351593669)
23. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol. 2009;99(6):319-323.
24. Asad J, Jacobson AF, Estabrook A, et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg. 2008;196(4):527-529.
25. Thanasoulis T, Brown A, Frazier T. The role of Oncotype DX™ assay on appropriate treatment for estrogen positive, lymph node negativeinvasive breast cancer. Presented at: 9th annual meeting of the American Society of Breast Surgeons; April 30-May 4, 2008; New York, NY.
26. Oratz R, Chao C, Skrzypczak S, Ory C, Broder M. Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer [abstract e11077]. J Clin Oncol. 2010;28(15S, May 20 suppl).
27. Interactive Clinical Intelligence Market Research. OncoReport: Medical Oncology T3 2007. http://www.icimrr.com/reports.html. Accessed November 18, 2010.
28. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003;21(22):4105-4111. (Pubitemid 46606177)
29. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer. 2004;40(3):403-410. (Pubitemid 38121278)
30. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-2268. (Pubitemid 38580348)
31. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-1496. (Pubitemid 20301179)
32. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27(32):5363-5369.
33. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-3696.
34. Martin M, Pienkowski T, Mackey J, et al Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313. (Pubitemid 40740554)
35. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25(23):3415-3420. (Pubitemid 47310877)
36. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-2830. (Pubitemid 46179473)
37. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113(3):529-535.
38. Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26(8):1239-1246.
39. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56(10):1-120.
40. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC [abstract 512]. J Clin Oncol. 2004;22(14S, July 15 suppl).
41. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110(3):489-498. (Pubitemid 47106136)
42. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr. 2001;(30):146-152.
43. Centers for Medicare & Medicaid Services. 2008 ASP Drug Pricing Files. http://www.cms.gov/McrPartBDrugAvgSalesPrice/01a-2008aspfiles. asp#TopOfPage. Accessed September 28, 2010.
44. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25-32. (Pubitemid 38141890)
45. Miles D, Chan A, Romieu G, et al. Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC) [abstract 41]. Cancer Res. 2009;69(24 suppl).
46. Waeber M, Castiglione-Gertsch M, Dietrich D, et al Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol. 2003;14(8):1215-1221. (Pubitemid 37039046)
47. Katz S, Crawford M, Mauro A, eds. CPI Detailed Report. Data for December 2009. Bureau of Labor Statistics. http://www.bls.gov/cpi/cpid0912.pdf. Accessed October 26, 2010.
48. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? health economics and the presidential candidates. N Engl J Med. 2008;358(7):661-663. (Pubitemid 351240744)
49. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920-927. (Pubitemid 44315984)
50. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of costeffectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518-528. (Pubitemid 39390832)
51. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667-677. (Pubitemid 41667135)
52. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641. (Pubitemid 36898950)
53. Broder MS, Yermilov I, Ko CY, Maggard MA, Ory C, Keeler EB. Does improving quality of care save money? Review of the cost effectiveness of a national set of quality indicators. Poster presented at: ISPOR 14th Annual International Meeting; May 16-20, 2009; Orlando, FL.
54. MCOL. HMO enrollment. Managed care fact sheets. http://www. mcareol.com/factshts/factnati.htm. Accessed November 12, 2010.
55. Banthin JS, Taylor AK. Research Findings #15: HMO Enrollment in the United States: Estimates Based On Household Reports, 1996. January
56. Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality. http://www.meps.ahrq.gov/data-files/publications/rf15/rf15.shtml. Accessed December 8, 2010.
57. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888-897. (Pubitemid 351881955)
58. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1107-1117.
59. Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009;43(3):444-452.
60. Jansen SJ, Kievit J, Nooij MA, Stiggelbout AM. Stability of patients'preferences for chemotherapy: the impact of experience. Med Decis Making. 2001;21(4):295-306. (Pubitemid 32652493)
61. Love N, Ravdin P, Hortobagyi G, et al. Influence of prior therapy on breast cancer survivors' preferences for adjuvant systemic therapy in hypothetical scenarios [ASCO abstract 591]. J Clin Oncol. 2004;22(suppl).
62. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
63. Hornberger J, Lyman GH, Chien R. Economic implications of 21-gene recurrence score assay: US multicenter experience [letter]. J Clin Oncol. 2010;28(22):e382.